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PURPOSE. To investigate possible roles of T helper (Th) cells, regulatory T cells (Tregs), and the
recently mapped Th-like Tregs in patients with polypoidal choroidal vasculopathy (PCV).
METHODS. In this prospective case-control study, we obtained fresh venous blood from
patients with PCV (n ¼ 24), age-matched healthy controls (n ¼ 32), and patients with
neovascular AMD (n ¼ 45). All participants underwent a comprehensive ocular examination
including fluorescein and indocyanine green angiography for where retinal disease was
suspected. Using flow cytometry, we identified Th subsets, Tregs, and Th-like Tregs. Plasma
samples were stored at 808C to investigate plasma cytokines of interest.
RESULTS. Compared to healthy controls, patients with PCV had lower percentages of Tregs
(8.7% 6 2.8% vs. 7.3% 6 1.7%, P ¼ 0.027), which were significantly more Th2-like polarized
(42.6% 6 13.3% vs. 50.5% 6 13.0%, P ¼ 0.029). These changes differed from that observed in
neovascular AMD, which compared to healthy controls had fewer Th1/Th17 cells (3.6% 6
2.7% vs. 2.4% 6 2.5%, P ¼ 0.049), comparable Treg levels, and no distinct polarization of Th-
like Tregs. Because of these findings, we measured plasma IL-4 and IL-33 levels. Plasma IL-33
in patients with PCV (median 0.30 pg/mL) was twice as high compared to healthy controls
(median 0.16 pg/mL; P ¼ 0.037).
CONCLUSIONS. PCV associate with diminished Tregs that are polarized more into a Th2-like
phenotype. This is correlated to IL-33 levels, which we also find increased in patients with
PCV. Our findings suggest a possible role for Th2-like Tregs and IL-33 in PCV.
Keywords: polypoidal choroidal vasculopathy, neovascular age-related macular degeneration,
t cells, interleukin-33
Polypoidal choroidal vasculopathy (PCV) is an exudativemaculopathy first described in 1982 by Lawrence Yannuz-
zi.1 The main features of PCV are the branching choroidal
vessels and the aneurysm-like acquired polypoidal lesions.2,3
Massive hemorrhages are common and can originate from
polypoidal ruptures.4,5 In patients with an initial diagnosis of
neovascular AMD (nAMD) who undergo indocyanine green
angiography (ICGA), PCV is seen in 5% to 10% of Caucasians
and in ~50% of Asians.4,6,7 Together, PCV and neovascular AMD
are the most common reason of irreversible vision loss in
developed countries.4,7
Aging, drusen-formation, complement, and immune dys-
function facilitate development of AMD.8–11 Progression to late-
stage AMD with choroidal neovascularization (CNV) is the
consequence of a complex immunological play: ocular aging,
immunologic aging, and immunologic dysfunction promote
angiogenesis through VEGF expression.8–11 Etiologic aspects of
PCV remains largely unknown. Tong et al.12 found increased
intraocular VEGF levels in both neovascular AMD and PCV, but
significantly lower in PCV than in neovascular AMD. Zeng et
al.13 found higher levels of serum matrix metalloproteinases 2
and 9 in patients with PCV than in patients with neovascular
AMD. Lafaut et al.14 identified islands of lymphocytic infiltration
around the aneurysmal vessel dilations in PCV specimens.
Although these findings give some insight and suggest a
possible role for immunologic dysfunction in PCV, the larger
picture remains unclear.
Studies of experimental CNVs on mice and observational
studies in patients with neovascular AMD suggest that blood
leukocytes are important for CNV formation.15–23 Lechner et
al.20 found that complement proteins C3a, C4a, and C5a were
significantly increased in plasma of patients with neovascular
AMD, but not in patients with PCV. Liu et al.21 found that
complement protein C5a promotes CD4þ T cell expression of
IL-17 and IL-22. In addition, in vitro studies demonstrate that
activated T cells upregulate RPE expression of complement
proteins and chemokines.22,23 These interesting findings propel
an attention toward T cells in AMD research.
T helper (Th) cells are CD4þ T cells that release cytokines to
orchestrate immunologic activity of other immune cells.24 Th
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cells can be categorized into functional subtypes: Th1 cells
promote activities of macrophages and cytotoxic T cells, Th2
cells promote activities of B cells and eosinophils, and Th17
cells produce IL-17 and promote inflammation and autoimmu-
nity. Regulatory T (Treg) cells are CD4þ T cells that modulate
the immune system, including the activities of the Th cells.25 In
2012, Duhen et al.26 described subpopulations of Tregs
mimicking Th cells and Halim et al.27 recently characterized
these Th-like Treg subsets in functional details. Neither Th
subtypes, Tregs, or Th-like Treg subtypes have been charac-
terized in patients with PCV.
Our aim with this study was to map these aspects through
blood analysis of patients with PCV and compare to healthy
controls and patients with neovascular AMD. Interestingly,
patients with PCV had lower percentage of Tregs, which in
turn were more Th2-like. Because of these findings, we
decided to quantify plasma levels of the cytokines IL-4 and
IL-33: IL-4 induces Th polarization toward Th2 in general,24
whereas IL-33 has been implicated in a range of immune-
mediated as it causes the differentiation of Treg cells into Th2-
like Treg cells.28 Patients with PCV did not differ in plasma IL-4,
but had twice as high plasma IL-33. Taken together, we here
present important immunologic insight into a poorly under-
stood retinal disease.
METHODS
Study Design and Ethics
All aspects of this prospective case-control study follow the
tenets of the Declaration of Helsinki and ethical approval was
obtained by the Regional Committee of Ethics in Research of
the Region of Zealand (SJ-379). Prior to participation,
participants had the nature of the study explained and gave
oral and written informed consent. Participants were recruited
consecutively from our outpatient clinic at Department of
Ophthalmology, Zealand University Hospital, Denmark. Based
on our previous study on CD4þCXCR3þCCR6þ T cells in
patients with neovascular AMD,17 we calculated that at least 18
participants in each group was necessary to obtain sufficient
power (assuming a¼ 0.05, b¼ 0.8, and r¼ 2). Therefore, we
recruited at least 18 participants in each group and stopped
further recruitment after a total of 110 participants.
Participant Eligibility, Clinical Information, and
Retinal Diagnosis
Participants were recruited if they had either PCV in one or
both eyes, neovascular AMD in one or both eyes, or healthy
retinas in both eyes (healthy controls). Healthy controls were
recruited among biologically unrelated relatives to the patients.
This was an intentional strategy to better match the control
group to the patient groups, as we have previously found that
lifestyle factors can potentially influence systemic immunolo-
gy.29,30 Participants were included if they fulfilled following
criteria to avoid ongoing immune activity: no cancer, no
immune disease, no infectious disease, and no chemo- or
immunotherapy for any reason. Because this study investigated
Th cell polarization, we also did not include any participants
with asthma. Patients with recent onset of CNV were not
included because of acute immune activity.19 Patients in
ranibizumab or aflibercept therapy were only included 4 or 8
weeks after since last injection, respectively, to avoid potential
interaction with the antibodies used for flow cytometry. All
participants were interviewed to obtain data on lifestyle and
medical history. Lifestyle factors noted were smoking habits,
alcohol consumption, body mass index, and physical activity.30
Medical data were crosschecked with the electronic patient
record to ensure accuracy. Participants were examined using
slit-lamp biomicroscopy, digital fundus photography, and
spectral-domain optical coherence tomography (OCT), and
retinal angiography (both fluorescein and indocyanine green)
where CNV was suspected. We used the following definition
for our groups:
 Healthy controls: Less than 10 small drusen (diameter
<63 lm) and no pigment abnormalities.31
 Neovascular AMD: Fibrovascular pigment epithelium
detachments and choroidal neovascular membranes with
subretinal or sub-RPE hemorrhages or fibrosis.31
 PCV: One or more polyps in early-phase ICGA with a
hypofluorescent halo and with/without BVN. Other
stigmata used to support the diagnosis were orange-red
focal subretinal polyp-like structures, pulsation of polyps
on ICGA video, and a protrusion from the choroid
elevating RPE from the Bruch’s membrane observed on
OCT.7
Blood Sampling
Venous blood was sampled from antecubital veins in separate
EDTA and lithium-heparin coated tubes. EDTA stabilized blood
was used for flow cytometric analyses within 4 hours after
blood sampling. One lithium-heparin coated tube was used for
routine C-reactive protein measurement. Other tubes with
lithium heparin stabilized blood were centrifuged for 15
minutes at 1500 G after which plasma was isolated and stored
at 808C for later quantification of plasma cytokines.
Flow Cytometry
We obtained the white blood cell count using an automated
hematology analyzer (Sysmex KX-21N; Sysmex Corp., Kobe,
Japan) to calculate blood volume necessary to obtain 53 105
white blood cells in each test tube. The red blood cells were
lysed in 1% lysis buffer (Nordic Biosite AB, Ta¨by, Sweden) for
10 minutes in the dark at room temperature. We then washed
the cells three times by first centrifuging for 5 minutes at 500
g, decanting the supernatant, and then resuspending the cells
in an isotonic buffer (BD FACSFlow; BD Biosciences, Franklin
Lakes, NJ, USA). We then added marker-specific monoclonal
antibodies to the sample tube and added fluorochrome-
matched negative isotypes were added to a separately
prepared tube (Supplementary File S1). Tubes were incubated
in dark at room temperature for 20 minutes, after which the
cells were washed and resuspended in an isotonic buffer (BD
Biosciences). Stained cells were analyzed using flow cytom-
etry (BD Biosciences) with a sample size gated for 100,000
singlet leukocytes. We used analytical software (Kaluza
version 1.5.20365.16139; Beckman Coulter Inc., Pasadena,
CA, USA) for all flow cytometric analyses. Two independent
evaluators (YS, MKN) performed all analyses completely
blinded to each participant’s condition and each other. CD4þ
T cells were identified and gated based on their CXCR3 and
CCR6 expression (Supplementary File S2). Zhang et al.32
studied Th cell subsets in humans and found that
CD4þCXCR3þCCR6 cells had characteristics of Th1,
CD4þCXCR3CCR6 had characteristics of Th2, and that
CD4þCXCR3CCR6þ had characteristics of Th17. We also
measured the CD4þCXCR3þCCR6þ cells, which may reflect
the Th1/Th17 cell subset (Supplementary file S2).27 Treg cells
were identified as CD4þCD127lowCD25high cells (Fig. 1),18 and
Th subsets in Treg cells (Th-like Tregs) were determined
(Supplementary File S3).27 Nonspecific signaling was elimi-
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nated using the corresponding negative isotype control at a
threshold of 1%.
Plasma Cytokine Assays
IL-4 and IL-33 were quantified using the commercially available
human assays from MSD (U-PLEX, Meso Scale Diagnostics,
Rockville, MD, USA). The assays were performed per the
manufacturer’s instructors and recommendations (Supplemen-
tary File S4). Prepared plates were immediately read on a
commercial instrument (QuickPlex SQ120; Meso Scale Diag-
nostics), which converts luminescence values to plasma
concentrations of the cytokines measured based on the
predefined concentrations in calibrators. Duplicate measure-
ments allowed sample-specific calculation of the coefficient of
variation (CV), which we used as a guide to reanalyze any
samples with high CV (>20%). Overall quality was satisfactory
(CV mean 6 SD: IL-4¼ 5.6% 6 4.4%; IL-33¼ 5.6% 6 4.5%). No
extreme outliers were found for plasma IL-4. Two cases of
extreme outliers (2.3 pg/mL and 8.7 pg/mL) for plasma IL-33
were excluded from the analyses.
Statistical Analysis
All statistical analyses were made using statistical software
(SPSS version 23; IBM Corp., Armonk, NY, USA). Mean and
standard deviation (SD) and parametric tests were used where
normal distribution was present, and otherwise median and
interquartile range (IQR) and nonparametric tests were used.
Categoric variables were presented in numbers and percent-
ages and compared between groups using the v2 test or
Fisher’s exact test when dealing with small categories (n < 5).
P-values below 0.05 were interpreted as sign of statistical
significance. Figures were made using graphing software
(Prism version 7; GraphPad Software Inc., San Diego, CA,
USA).
RESULTS
Study Population
We recruited 110 participants in total. Nine were excluded due
to suspected ongoing immune response or because samples
failed flow cytometry (Supplementary File S5). Remaining
participants were all included for our analyses (Table 1).
Groups did not differ significantly in demographics, comor-
bidities, and lifestyle factors (Table 1).
Differences in CD4þ T Helper Cell Polarization
Compared to healthy controls, fewer Th1/Th17 cells
(CXCR3þCCR6þ) were observed in patients with neovascular
AMD (P¼ 0.049, independent samples t-test; Table 2). Patients
with PCV did not differ significantly from healthy controls, but
we did observe a trend toward higher Th2 (P ¼ 0.059,
independent samples t-test).
Lower Tregs and Higher Th2-like Tregs in Patients
With PCV
We used CD25high and CD127low in CD4þ lymphocytes to
identify and quantify the Treg population (Fig. 1). In healthy
controls, we found that mean: 8.7% (SD: 2.8%) of CD4þ T cells
were Tregs, which was similar to the level in patients with
neovascular AMD (mean: 8.7%, SD: 2.1%, P ¼ 0.96, indepen-
dent samples t-test). Patients with PCV had significantly fewer
Tregs than healthy controls (mean: 7.3%, SD: 1.7%, P¼ 0.027,
independent samples t-test) with a significantly lower distri-
bution variance (F¼4.029, P¼0.050, Levene’s test for equality
of variances).
In Tregs, we investigated Th-like populations (Supplemen-
tary File S3). Healthy controls and patients with neovascular
AMD did not differ significantly in any of the measured
FIGURE 1. Identification and quantification of Treg and comparison between healthy controls and patients with PCV or patients with nAMD. (A)
CD4þ T cells were identified as CD4þ lymphocytes. (B) Treg were identified as CD4þ T cells that were CD25high and CD127low. (C) Treg levels did
not differ significantly between healthy controls and patients with nAMD (P ¼ 0.96, independent samples t-test), but was significantly lower in
patients with PCV than in healthy controls (P¼ 0.027, independent samples t-test, signified with an asterisk). Whiskers represent mean and 95%
confidence interval.
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populations (Table 3). Patients with PCV had significantly
higher Th2-like Treg (P ¼ 0.029, independent samples t-test)
and significantly lower Th17-like Treg (P¼ 0.039, independent
samples t-test).
Higher Plasma IL-33 in Patients With PCV
Because of our findings on Th2-like Treg in patients with PCV,
we shifted our focus to plasma levels of cytokines IL-4 and IL-
33. Plasma IL-4 did not differ between healthy controls and
patients with PCV or neovascular AMD (Fig. 2). Patients with
PCV had significantly higher and almost twice as high median
IL-33 0.30 pg/mL compared to the healthy controls (median
0.16 pg/mL; P ¼ 0.037, Mann-Whitney U test), while patients
with neovascular AMD had levels comparable to that in healthy
controls (P ¼ 0.55, Mann-Whitney U test; Fig. 2). In patients
with PCV, where we observed a higher IL-33 and Th2-like Treg
cells, we also found a correlation trend between higher plasma
IL-33 and higher percentage of Th2-like cells in the Treg
population (q ¼ 0.4, P ¼ 0.062, Spearman’s correlation).
Patient Characteristics in Relation to Immunologic
Findings
Since we observed a trend (P ¼ 0.057, Fisher’s Exact test)
toward higher prevalence of type 2 diabetes as a comorbidity
in patients with PCV and patients with neovascular AMD, we
compared all our findings between those with and without
type 2 diabetes and did not find any significant differences (P >
0.1 for all comparisons).
Expectedly, groups differed significantly in the proportion
of AREDS2-based supplement users (n ¼ 3 [13% of patients
with PCV]; n ¼ 13 [29% of patients with neovascular AMD];
and n ¼ 0 [0% of healthy controls], P < 0.001, Fisher’s Exact
test). To investigate if AREDS2-based supplement use influ-
enced our immunological measurements, we compared
patients who used AREDS2-based supplements to patients
who did not use AREDS2-based supplements (Supplementary
File S6). No differences were observed in patients with PCV. In
patients with neovascular AMD, plasma IL-4 was significantly
higher among AREDS2-based supplement users (median 0.30
pg/mL; IQR: 0.11–0.38 pg/mL) than those who did not use
TABLE 1. Participant Characteristics
Healthy Controls
(n ¼ 32)
Patients with PCV
(n ¼ 24)
Patients With nAMD
(n ¼ 45) P Value
Demographics
Age (y), mean (SD) 73.4 (7.9) 72.3 (7.7) 75.4 (7.2) 0.24*
Females, n (%) 18 (56) 16 (67) 24 (53) 0.56†
Comorbidities
Hypertension, n (%) 11 (34) 11 (46) 24 (53) 0.26†
Cardiovascular disease, n (%) 9 (20) 5 (21) 9 (16) 0.85†
Hypercholesterolemia, n (%) 12 (38) 9 (38) 11 (24) 0.37†
Type 2 diabetes, n (%) 0 (0) 3 (13) 6 (13) 0.057‡
Lifestyle factors
Smoking, n (%) 0.29‡
Active 5 (15) 8 (33) 13 (29)
Previous 14 (44) 12 (50) 18 (40)
Never 13 (41) 4 (17) 14 (31)
Alcohol consumption, units, median (IQR) 4 (2–7) 4 (1–14) 4 (1–9) 0.72§
Body mass index, mean (SD) 25.3 (4.4) 25.3 (3.7) 26.1 (4.2) 0.73*
Physically active, n (%) 22 (69) 13 (54) 24 (53) 0.36†
Smoking habits were categorized into one of three groups: active, previous (>100 cigarettes during lifetime and ceased smoking >12 months),
or never. Alcohol consumption is quantified using units/week (1 unit¼ 15 mL/12 g pure ethanol). Body mass index is calculated as weight divided
by height squared. Being regularly physically active is categorized using a simple question for epidemiologic studies previously validated in Danish
patients with AMD.29
* Statistical comparisons are made using 1-way ANOVA.
† Statistical comparisons are made using v2-test.
‡ Statistical comparisons are made using Fisher’s Exact test because of categories with 4 cases.
§ Statistical comparisons are made using Kruskal-Wallis’ test.
TABLE 2. Comparison Between Healthy Controls and Patients With PCV or Patients With nAMD in CD4þ T Cell Expression of T Helper Cell Markers
CXCR3 and CCR6
Healthy Controls Patients With PCV P Value* Patients With nAMD P Value†
CD4þCXCR3þCCR6 (Th1) 4.2 (3.6) 4.5 (3.4) 0.76 3.1 (2.2) 0.11
CD4þCXCR3CCR6 (Th2) 63.6 (10.9) 69.4 (11.6) 0.059 68.8 (11.8) 0.053
CD4þCXCR3CCR6þ (Th17) 28.6 (9.4) 23.3 (10.5) 0.52 25.8 (10.2) 0.22
CD4þCXCR3þCCR6þ (Th1/Th17) 3.6 (2.7) 2.7 (2.7) 0.26 2.4 (2.5) 0.049
All values are presented as a percentage of the total CD4þ T cell population in means and standard deviations in parentheses. Boldface P values
indicate statistically significant differences from healthy controls.
* Statistical comparisons are made using independent samples t-test between healthy controls and patients with PCV.
† Statistical comparisons are made using independent samples t-test between healthy controls and patients with neovascular AMD.
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AREDS2-based supplements (median 0.09 pg/mL; IQR: 0.07–
0.13 pg/mL; P ¼ 0.002, Mann-Whitney U test).
Patients were followed in the clinic in median 16 months
(IQR: 6–34 months) prior to blood sampling (patients with
PCV: median 16 months [IQR: 4–34 months]; patients with
neovascular AMD: median 16 months [IQR: 9–32 months]; P¼
0.313, Mann-Whitney U test). We found no correlations
between time from disease presentation to sampling and to
any of our immunologic measurements (P > 0.1 for all
correlations, Spearman’s correlation). To study disease dura-
tion in a different manner, we stratified our patients with PCV
according to whether they had polypoidal lesions with strong
presence of BVNs (where we assume that the disease is
relatively more advanced; n¼14) or polypoidal lesions without
or very faint BVNs (where we assume that the disease is at an
earlier stage; n¼ 10; Supplementary File S7). These groups did
not differ significantly in any of the immunologic measure-
ments.
DISCUSSION
In line with our previous findings in patients with neovascular
AMD,17,33 we find association between neovascular AMD and
lower CD4þCXCR3þ and CD4þCXCR3þCCR6þ. CXCR3þ T cells
are particularly interesting since they migrate toward areas of
inflammation,34 CXCR3-CXCL10 interaction activates down-
stream pathways that inhibits VEGF-induced endothelial
motility and tube formation,35 and age-related parainflamma-
tion in RPE leads to downregulation of CXCL10 expression.36
Dysregulation of CXCR3-CXCL10 axis have been suggested as a
biomarker for AMD specifically and a therapeutic target in
diseases with uncontrolled angiogenesis in general.33,35,37
Dysregulation of CXCR3 in CD4þ T cells in patients with
neovascular AMD may be specific to the CCR6þ subset and
reflect a lower systemic Th1/Th17 population. Experimental
studies of the Th1/Th17 population in patients with AMD are
warranted to understand its contribution for CNV develop-
ment.
Dysregulation of CXCR3 in CD4þ T cells did not seem to
play a significant role in PCV. Instead, our results suggest that
PCV is a disease characterized by diminished Tregs, increased
Th2-like polarization of the Tregs, and increased plasma IL-33.
Balancing an effective immune response with self-tolerance
and setting the proper magnitude of the immune response is
the key role of Tregs.38 Hence, diminished or dysfunctional
Tregs are linked to diseases with an autoimmune component
(e.g., allergies and asthma).39,40 This regulatory activity is also
present in the retina, where RPE induces Tregs to suppress the
intraocular activity of proinflammatory leukocytes.41 RPE
induced Tregs secrete high levels of immunoregulatory
cytokines which suppress Th1 and Th17 activity.42 These
mechanisms shed explanatory light on our results: well-
functioning Treg activity in patients with neovascular AMD
may lead to Th1/Th17 downregulation to dampen the ongoing
FIGURE 2. Comparison between healthy controls and patients with PCV or patients with nAMD in plasma levels of IL-4 and IL-33. (A) Plasma IL-4
levels did not differ significantly between the groups. Whiskers represent median and interquartile range. (B) Plasma IL-33 levels did not differ
significantly between healthy controls and patients with nAMD (P¼ 0.55, Mann-Whitney U test), but was significantly higher in patients with PCV
than in healthy controls (P ¼ 0.033, Mann-Whitney U test, signified with an asterisk). Whiskers represent median and interquartile range.
TABLE 3. Comparison Between Healthy Controls and Patients With PCV or Patients With nAMD in Treg Th-like Cells
Healthy
Controls
Patients
With PCV P Value*
Patients
With nAMD P Value†
CD4þCD25highCD127lowCXCR3þCCR6 (Th1-like Treg) 2.5 (2.2) 2.3 (1.8) 0.69 1.8 (1.6) 0.12
CD4þCD25highCD127lowCXCR3CCR6 (Th2-like Treg) 42.6 (13.3) 50.5 (13.0) 0.029 45.4 (14.9) 0.39
CD4þCD25highCD127lowCXCR3CCR6þ (Th17-like Treg) 51.4 (12.6) 44.6 (11.7) 0.039 50.4 (14.4) 0.72
CD4þCD25highCD127lowCXCR3þCCR6þ (Th1/Th17-like Treg) 3.4 (2.9) 2.6 (2.6) 0.29 2.4 (2.1) 0.069
All values are presented as percentage of the total Treg population in means and standard deviations in parentheses. Bold P values indicate
statistically significant differences from healthy controls.
* Statistical comparisons are made using independent samples t-test between healthy controls and patients with PCV.
† Statistical comparisons are made using independent samples t-test between healthy controls and patients with neovascular AMD.
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proinflammatory angiogenetic activity. Diminished Tregs in
patients with PCV allow a different direction of angiogenesis
and may explain why studies find series of intraocular cytokine
expression in PCV.43,44 Zhao et al.43 found significantly higher
levels of the proinflammatory IL-1b in the vitreous of eyes with
PCV when compared to controls (eyes with idiopathic
epiretinal membrane) and patients with neovascular AMD.
Sasaki et al.44 found significantly higher levels of a range of
proinflammatory cytokines in the aqueous of eyes with PCV,
including IL-4 which suggests a local Th2-like response. Is PCV
a Th2-mediated disease? Gold-standard diagnosis of PCV
requires ICGA and consequently very few epidemiologic
studies exist; therefore, it is currently not possible to draw
clear links to other Th2- or Th2-like Treg-related diseases.
In 2015, MacDonald et al.28 reported the first Th2-like Treg-
associated disease in humans (systemic sclerosis: an autoim-
mune disease with dysfunctional angiogenesis despite in-
creased VEGF).28 Levels of Tregs were similar in patients
with systemic sclerosis when compared to healthy controls,
but the Tregs in patients were more CXCR3CCR6 and
expressed Th2-associated cytokines. Halim et al.27 found that
Th2-like Tregs have greater migratory ability and a higher
viability and blasting capacity through STAT5 phosphorylation,
which promotes angiogenesis.45 Treg polarization into Th2-like
phenotype is facilitated by IL-33.28,46 Although no previously
published reports have investigated IL-33 in patients with PCV,
it is interesting to note that Genentech, Inc. have applied for
and received a patent for the use of anti-IL-33 for PCV.47
Pachychoroid neovasculopathy is a new clinical definition
of CNV-diseases associated with a thick dilated choroid,
wherein PCV constitutes a large and important proportion of
cases.48 By post-hoc reviewing our PCV cases using the
definition by Miyake et al.,49 17 (71%) patients with PCV
could be classified with the diagnosis pachychoroid neo-
vasculopathy. We found that these patients do not have AMD-
like features of lower CXCR3þ and CXCR3þCCR6þ, but have
lower Tregs than healthy controls (P ¼ 0.014), which were
increasingly Th2-like polarized (P ¼ 0.036), and had increased
plasma IL-33 levels (median 0.45, IQR: 0.16–0.66) at a near-
significant level (P ¼ 0.060). We here provide rare immuno-
logic insight into pachychoroid neovasculopathy and together
with the genetic study by Miyake et al.,49 our collective results
suggest that pachychoroid neovasculopathy may be etiologi-
cally distinct from neovascular AMD.
Important limitations of this study should be considered.
First, the observational, cross-sectional, and exploratory nature
of this study can only correlate possible mechanisms and we
cannot infer conclusively on causality. Second, Th subtypes are
distinguished by their functional properties (e.g., cytokine
secretion). We did not perform functional analyses of Th
subtypes defined in this study, but instead relied on the
accuracy of the functional studies made by others.27,28 Third,
we did not find any relationship between disease duration and
the immunological findings, but these calculations are based
on the assumption that time of disease onset equals the time of
disease presentation at our clinic. Theoretically, we cannot
know how long the disease was present prior to presentation
at our clinic. Quiescent lesions—especially small peripheral
polyps without additional features such as hemorrhages—may
be relatively asymptomatic, at least in the beginning stages of
the disease. Finally, investigations of systemic immunity in
elderly patients must carefully select their control group since
lifestyle factors may significantly influence the results.30 A
strength of this study was our strategy of recruiting among
biologically unrelated relatives to the patients to better match
the control group in terms of lifestyle factors. We measured
several aspects of lifestyle factors to provide insight into the
validity of this approach (smoking, body mass index, alcohol
use, and physical activity), which all were comparable
between the groups. However, considering that dietary habits
also may play a role in AMD,50–52 further validation of the
strength of this control group recruitment strategy should
include an assessment of dietary habits.
Taken together, we conclude that PCV associates with
systemic immunologic changes that differ from that seen in
neovascular AMD. Patients with PCV have diminished Tregs
that are increasingly polarized into a Th2-like phenotype
wherein IL-33 secretion may play an important role. Experi-
mental studies are warranted to determine causality and
whether these immunologic alterations can be used as targets
for treatment.
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